Trastuzumab emtansine (T-DM1) in advanced cancers with <i>HER2 </i>mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.
Subotheni Thavaneswaran(The University of Sydney), David M. Thomas(New South Wales Department of Health), Lucille Sebastian(Heidelberg University), Rosemary Harrup(University of Tasmania), Michael P. Brown(South Australia Pathology), Peter Grimison(The University of Sydney), Antony Mersiades(The University of Sydney), Kenneth J. O’Byrne(Translational Research Institute), Frank Lin(The University of Sydney), John P. Grady(Garvan Institute of Medical Research), Adnan Nagrial(Westmead Hospital), Chee Khoon Lee(The University of Sydney), John Simes(The University of Sydney), Jayesh Desai(Peter MacCallum Cancer Centre), Michael Millward(The University of Western Australia), Maya Kansara(Garvan Institute of Medical Research), Anthony M. Joshua(St Vincent's Hospital Sydney), Paul Craft(Canberra Hospital), David Espinoza(The University of Sydney), Sarah Chinchen(The University of Sydney)
Cited by 2
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k